ONCOLOGY LETTERS 20: 323, 2020

Abstract. Numerous studies have reported that the long non‑coding RNA (lncRNA) small nucleolar RNA host gene 6 (SNHG6; ENSG00000245910) participates in the development of malignant tumors. However, the underlying mechanism of SNHG6 in the development of melanoma remains unknown. Thus, the present study aimed to investigate the biological role of SNHG6 in the progression of melanoma. SNHG6 expression in melanoma tissues and cells was assessed using a bioinformatics approach and reverse transcription‑quantitative PCR analysis. Cell viability was determined using the Cell Counting Kit‑8 and colony formation assays. The correla‑tion between microRNA (miR)‑101‑3p, SNHG6 and RAP2B expression levels was assessed using Pearson's correlation analysis. Bioinformatic analysis and luciferase reporter assay were utilized to confirm the interaction between miR‑101‑3p and SNHG6 or RAP2B. The Transwell assay was conducted to examine the migratory and invasive activities of mela‑noma cells. In the present study, SNHG6 expression was upregulated in melanoma tissues and cell lines, and SNHG6 silencing suppressed melanoma cell viability, migration and invasion. SNHG6 was directly bound to miR‑101‑3p, which interacted with RAP2B. In addition, miR‑101‑3p expression was negatively correlated with SNHG6 or RAP2B expression. miR‑101‑3p silencing partially abrogated the suppressive effect of SNHG6‑knockdown on RAP2B expression. Moreover, the data demonstrated that RAP2B overexpression reversed the inhibitory effects on melanoma cell proliferation, migration and invasion induced by SNHG6 silencing. In conclusion, the present study identified that SNHG6 accelerated melanoma progression via regulating the miR‑101‑3p/RAP2B axis. Thus, the SNHG6/miR‑101‑3p/RAP2B signaling pathway may be a novel therapeutic target for melanoma.

Introduction

Melanoma is the most malignant and aggressive skin cancer type originating from melanocytes that produce pigments (1). Recently, its morbidity has increased considerably world‑wide (2,3). It is estimated that each year there are 150,000 new cases and 50,000 mortalities from melanoma, world‑wide (4,5). Although various novel treatments, including adjuvant immunotherapy and gene‑targeted therapy, have been developed for patients with melanoma, the 5‑year survival rate of patients with metastatic melanoma remains low at 18% (6). Therefore, it is imperative to examine the pathogenesis of melanoma in order to improve the prognosis in patients.

Long non‑coding RNAs (lncRNAs) are a class of non‑coding RNAs (ncRNAs) that contain >200 nucleo‑tides (7). Recent studies have reported that the dysregulation of lncRNAs is involved in the development of multiple tumors, including melanoma (8,9). It has been reported that lncRNA small nucleolar RNA host gene 6 (SNHG6; ENSG00000245910) is involved in the progression of various types of cancer. For example, SNHG6 acts as an oncogene to promote the tumorigenesis and development of colorectal cancer (10). Furthermore, SNHG6 promotes cholangiocarcinoma (CCA) cell progression, and its upregu‑lation is associated with poor overall survival in patients with CCA (11). SNHG6 facilitates the proliferation and invasion of breast cancer cells by sponging microRNA (miRNA/miR)‑26a and by upregulating vasodilator stimulated phosphoprotein expression (12). However, the mechanism via which SNHG6 participates in melanoma remains unknown.

miRNAs are a class of small ncRNAs with a length of 20‑22 nucleotides (13). Increasing evidence has revealed that miR‑101‑3p serves a suppressive role in various types of cancer. For example, miR‑101‑3p inhibits cervical cancer cell viability and apoptosis induction by downregulating JAK2 expression (14). In addition, miR‑101‑3p suppresses glioblastoma cell proliferation and migration by targeting tripartite motif‑containing 44 (15). The present study inves‑tigated the function of miR‑101‑3p in the development of melanoma.

The present study aimed to investigate whether SNHG6 is involved in the progression of melanoma. Cell Counting Kit‑8 (CCK‑8), colony formation and Transwell assays were

Long non‑coding RNA SNHG6 promotes tumorigenesis in melanoma cells via the microRNA‑101‑3p/RAP2B axis

HONG ZHOU, LINGQIAO LI, YINGQIAN WANG and DEWEI WANG

Department of Plastic Surgery and Burn, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213000, P.R. China

Received April 16, 2020; Accepted August 18, 2020

DOI: 10.3892/ol.2020.12186

Correspondence to: Dr Lingqiao Li, Department of Plastic Surgery and Burn, The First People's Hospital of Changzhou, 185 Juqian Street, Tianning, Changzhou, Jiangsu 213000, P.R. ChinaE‑mail: lingqiaoli7878@163.com

Key words: long non‑coding RNA small nucleolar RNA host gene 6, melanoma, microRNA‑101‑3p, RAP2B

ZHOU et al: lncRNA SNHG6 PROMOTES TUMORIGENESIS VIA THE miR‑101‑3p/RAP2B AXIS IN MELANOMA2

performed to determine the biological function of SNHG6 in melanoma.

Materials and methods

Clinical specimens. A total of 25 pairs of melanoma and adja‑cent healthy tissues (3‑5 cm away from the tumor) were collected from patients (15 men and 10 women) with a mean age of 51 years (age range, 41‑62 years) who underwent surgical resec‑tion at The First People's Hospital of Changzhou (Changzhou, China) between September 2016 and October 2018. All tissues were immediately stored in liquid nitrogen at ‑80˚C until further use. The present study was approved by the Ethics Committee of The First People's Hospital of Changzhou and written informed consent was obtained from all patients.

Cell culture. Human epidermal melanocytes HEMa‑LP were purchased from Thermo Fisher Scientific, Inc. Melanoma cell lines (A375, SK‑MEL‑5 and M14) and 293T cells were all purchased from the American Type Culture Collection. Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS; all purchased from Gibco, Thermo Fisher Scientific, Inc.), at 37˚C in 5% CO2.

Cell transfection. The short hairpin (sh)RNA sequence targeting SNHG6 (shSNHG6), the negative control sequence (shNC), miR‑101‑3p mimics (5'‑GCA GGG CAC GAC UGA UCU UGG‑3'), NC mimics (5'‑GGA AGU CAU CCA AUG UGC AUU‑3'), miR‑101‑3p inhibitor (5'‑UCG CUC GGU CCY GAU CGG GAG‑3') and NC inhibitor (5'‑UCC CUG GUU GCA GAU CGC GAA‑3') were purchased from Shanghai GenePharma Co., Ltd. SNHG6 and RAP2B overexpression were performed by subcloning the SNHG6 and RAP2B full length sequences into the pcDNA3.1 plasmid (Invitrogen; Thermo Fisher Scientific, Inc.). A375 and SK‑MEL‑5 cells (2x105 cells/well) were transfected with shSNHG6 (10 nM), shNC (10 nM), miR‑101‑3p mimics (10 nM), NC mimics (10 nM), miR‑101‑3p inhibitor (10 nM) or NC inhibitor (10 nM) using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). The transfected cells were used for subsequent experimentation 48 h post‑transfection. The transfection efficiency was measured using reverse transcription‑quantitative PCR (RT‑qPCR).

Cell Counting Kit‑8 (CCK‑8) assay. Cell viability was determined using the CCK‑8 assay kit (Dojindo Molecular Technologies, Inc.) according to the manufacturer's instruc‑tions. A375 and SK‑MEL‑5 cells (1x104 cells/well) were seeded into a 96‑well plate. Following incubation for 0, 24, 48 and 72 h at 37˚C, 10 µl CCK‑8 solution (Dojindo Molecular Technologies. Inc.) was added to each well, according to the manufacturer's instructions, and cells were incubated for 4 h at room temperature. The absorbance at 450 nm was deter‑mined using a microplate reader (Thermo Fisher Scientific, Inc.).

Colony formation assay. The transfected cells were seeded into 6‑well plates (200 cells/well) and cultured for 2 weeks at 37˚C until colony formation was observed. The cells were fixed in 4% paraformaldehyde and stained with 0.5% crystal

violet for 15 min at room temperature, respectively. The number of colonies was counted using a light microscope (magnification, x4).

Transwell experiment. The invasive ability of melanoma cells was analyzed using Transwell chambers (8.0‑µm pore size; EMD Millipore) and Matrigel®. Following transfection, the cells were incubated for 48 h at 37˚C and 3x104 cells were plated in the upper chambers of the Transwell plates in serum‑free medium. The Transwell membranes were pre‑coated with Matrigel for 1 h at room temperature. A total of 600 µl DMEM supplemented with 10% FBS was added to the lower chambers. Following incubation for 48 h at 37˚C, cells on the top of the membrane were gently scraped off using a cotton swab, and the invasive cells in the lower chamber were fixed in 4% formaldehyde, stained with 0.1% crystal violet both for 20 min at room temperature and counted under a light microscope (magnification, x200). The migration assay involved measurement of the number of migrating cells according to the aforementioned method, with the exception that the upper layer of the filter was not coated with Matrigel.

Dual‑luciferase reporter assay. StarBase V3.0 (http://star‑base.sysu.edu.cn/index.php) was used to validate the putative bindings between miR‑101 and SNHG6, or between miR‑101 and RAP2B 3'‑untranslated region (3'‑UTR). The pmirGLO‑SNHG6‑wild‑type (wt) or ‑mutant (mut) and pmirGLO‑RAP2B‑wt or ‑mut reporters were produced from Genepharm, Inc. Then, 293T cells (3x104 cells/well) were co‑transfected with luciferase reporter vectors and miR‑101‑3p mimics (10 nM) or miR‑NC (10 nM) using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). Following co‑transfection for 48 h at 37˚C, the relative luciferase activity was measured using a dual‑lucif‑erase reporter assay system (Promega Corporation). Firef ly luciferase activity was normalized to Renilla (Promega Corporation) luciferase gene activity.

RT‑qPCR. Total RNA was extracted from tissues and cell lines using TRIzol® reagent (Thermo Fisher Scientific, Inc.). The quality of the RNA was assessed using 1% agarose gel elec‑trophoresis and spectrophotometry. The RNA concentration was measured using a NanoDrop™ 2000 spectrophotometer (Thermo Fisher Scientific, Inc.). RNA (1 µg) was reverse transcribed into cDNA using the PrimeScript RT reagent kit (Takara Bio, Inc.) at 37˚C for 15 min. RT‑qPCR was performed using the SYBR Green kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) on the ABI 7500 Real‑time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) with the following thermocycling conditions: Initial denaturation at 95˚C for 3 min, followed by 40 cycles of denaturation at 95˚C for 30 sec, annealing at 60˚C for 30 sec, extension at 72˚C for 20 sec and a final extension at 72˚C for 5 min. GAPDH was used as an internal control for SNHG6 and RAP2B, while U6 was used as an internal control for miR‑101‑3p. The relative expression levels were calculated using the 2‑ΔΔCq method (16). The primer sequences were as follows: SNHG6 forward, 5'‑TTC ACC GAC ATA GTC TCT TG‑3' and reverse, 5'‑CCA TCA CTT GAC CTC CTT C‑3';

ONCOLOGY LETTERS 20: 323, 2020 3

miR‑101‑3p forward, 5'‑TTG AGG TTG CTT CAG TGA‑3' and reverse, 5'‑GGA GTA GAT GAT GGT TAG C‑3'; RAP2B forward, 5'‑TGA TGT TCT CCT TCG GTT CTT G‑3' and 5'‑TTC CTC CTC CTG ATG TCT TCT C‑3'; GAPDH forward, 5'‑AAC GGA TTT GGT CGT ATT G‑3' and reverse, 5'‑GGA AGA TGG TGA TGG GAT T‑3'; and U6 forward, 5'‑CTC GCT TCG GCA GCA CA‑3' and reverse, 5'‑AAC GCT TCA CGA ATT TGC GT‑3'.

Statistical analysis. All experiments were repeated three times independently. SPSS 19.0 software (SPSS, Inc.) was used to analyze the data. Data are presented as the mean ± SD. One‑way ANOVA followed by Tukey's post hoc test were used to compare differences between multiple groups. A paired Student's t‑test was used to compare differ‑ences between melanoma and adjacent normal tissues from patients with melanoma, while an unpaired Student's t‑test was used to compare differences between the experimental and control groups. The Kaplan‑Meier method and log‑rank test were performed to determine the overall survival rates and the survival curve. The mean expression of SNHG6 was used as the cut‑off value. Pearson's correlation analysis was used for analyzing the correlation among gene expression. P<0.05 was considered to indicate a statistically significant difference.

Results

SNHG6 expression is upregulated in melanoma tissues and cell lines. Initially, SNHG6 expression was examined in mela‑noma and healthy tissues. The expression levels of SNHG6 were significantly increased in melanoma tissues compared with those in healthy tissues (Fig. 1A). Patients with high SNHG6 expression exhibited a significantly lower survival rate compared with those with low SNHG6 expression (Fig. 1B). Subsequently, the expression levels of SNHG6 were investigated in melanoma cell lines. It was found that SNHG6 expression was significantly upregulated in melanoma cell lines (A375, SK‑MEL‑5 and M14) compared with HEMa‑LP

melanocytes (Fig. 1C). Therefore, the data demonstrated that SNHG6 expression was upregulated in melanoma cells and that high SNHG6 expression contributed to poor prognosis in patients with melanoma.

SNHG6‑knockdown decreases melanoma cell viability, migration and invasion. To investigate the role of SNHG6 in melanoma, loss‑of‑function assays were performed. A375 and SK‑MEL‑5 cell lines were used in the subsequent experiments due to the high expression of SNHG6. RT‑qPCR analysis identified that SNHG6 expression was significantly down‑regulated following the transfection of shSNHG6 in A375 and SK‑MEL‑5 cells (Fig. 2A). The CCK‑8 and colony forma‑tion assays indicated that SNHG6‑knockdown significantly suppressed the proliferation of A375 and SK‑MEL‑5 cells (Fig. 2B and C). Moreover, SNHG6 silencing significantly decreased the migratory and invasive activities of melanoma cells (Fig. 2D and E). Thus, it was concluded that SNHG6 may accelerate melanoma progression.

SNHG6 is a sponge for miR‑101‑3p. Using starBase, a binding site was identified between SNHG6 and miR‑101‑3p (Fig. 3A). RT‑qPCR analysis demonstrated that miR‑101‑3p expression was significantly increased in A375 cells transfected with miR‑101‑3p mimics (Fig. 3B). The luciferase experiments were conducted in 293T cells. A lower luciferase activity of the SNHG6‑wt luciferase reporter was observed in the miR‑101‑3p mimics group compared with that in the NC mimics group. However, no significant difference was observed in the lucif‑erase activity of SNHG6‑mut (Fig. 3C).

RT‑qPCR analysis revealed that miR‑101‑3p was significantly downregulated in melanoma tissues and cell lines compared with healthy melanocytes (Fig. 3D and E). Furthermore, SNHG6‑knockdown resulted in increased miR‑101‑3p expression in A375 cells (Fig. 3F), and SNHG6 overexpression significantly increased SNHG6 expression and suppressed miR‑101‑3p expression in A375 cells compared with control cells (Fig. 3G and H). It was also indicated that miR‑101‑3p expression was very strongly, negatively

Figure 1. SNHG6 expression is upregulated in melanoma tissues and cell lines. (A) RT‑qPCR analysis of the expression levels of SNHG6 in melanoma and healthy tissues. (B) Kaplan‑Meier analysis of the association between SNHG6 expression and the overall survival in patients with melanoma. (C) RT‑qPCR analysis of the relative expression levels of SNHG6 in melanoma cell lines (A375, SK‑MEL‑5 and M14) and HEMa‑LP melanocytes. **P<0.01 vs. healthy or HEMa‑LP. RT‑qPCR, reverse transcription‑quantitative PCR; SNHG6, small nucleolar RNA host gene 6.

ZHOU et al: lncRNA SNHG6 PROMOTES TUMORIGENESIS VIA THE miR‑101‑3p/RAP2B AXIS IN MELANOMA4

correlated with SNHG6 expression in melanoma tissues (Fig. 3I). Therefore, SNHG6 may downregulate the expression levels of miR‑101‑3p via direct interaction.

SNHG6 upregulates RAP2B expression by sponging miR‑101‑3p. Using starBase, RAP2B was predicted as a poten‑tial downstream target of miR‑101‑3p (Fig. 4A). Luciferase

reporter assays indicated that miR‑101‑3p mimics decreased the luciferase activity of RAP2B‑wt in 293T cells. However, no effects were noted in the luciferase activity of RAP2B‑mut (Fig. 4B). Transfection of miR‑101‑3p mimics further decreased RAP2B expression in A375 cells compared with transfection of NC mimics (Fig. 4C). In addition, RT‑qPCR analysis demonstrated that RAP2B expression was significantly

Figure 2. SNHG6‑knockdown decreases melanoma cell viability, migration and invasion. (A) Reverse transcription‑quantitative PCR of the relative SNHG6 expression transfected with shSNHG6 or shNC in A375 and SK‑MEL‑5 cells. (B) Cell Counting Kit‑8 and (C) colony formation assays (magnification, x4) of the proliferative ability of A375 and SK‑MEL‑5 cells transfected with shSNHG6 or shNC. Transwell assays of (D) the migratory (magnification, x200) and (E) invasive abilities of A375 and SK‑MEL‑5 cells (magnification, x200) transfected with shSNHG6 or shNC. *P<0.05; **P<0.01 vs. shNC. shNC, short hairpin RNA negative control; OD, optical density; SNHG6, small nucleolar RNA host gene 6.

ONCOLOGY LETTERS 20: 323, 2020 5

increased in melanoma tissues compared with healthy tissues (Fig. 4D). The results suggested that RAP2B expression was strongly, negatively correlated with miR‑101‑3p expression and strongly, positively correlated with SNHG6 expression in melanoma tissues (Fig. 4E and F). RT‑qPCR analysis indicated that miR‑101‑3p expression was significantly downregulated in A375 cells transfected with miR‑101‑3p inhibitor compared with in those transfected with the NC inhibitor (Fig. 4G). Additionally, the miR‑101‑3p inhibitor reversed the inhibi‑tory effects on RAP2B expression in A375 cells induced by SNHG6 silencing (Fig. 4H). In summary, the results suggested that SNHG6 promoted RAP2B expression by regulating miR‑101‑3p.

SNHG6 promotes melanoma progression by upregulating RAP2B expression. To clarify whether SNHG6 regulates melanoma progression via RAP2B, A375 cells were trans‑fected with pcDNA3.1/RAP2B and the transfection efficiency was assessed via RT‑qPCR analysis (Fig. 5A). CCK‑8 and colony formation assays indicated that RAP2B overexpres‑sion rescued the inhibition of cell proliferation caused by SNHG6‑knockdown in A375 cells (Fig. 5B and C). Similarly, the migratory and invasive activities of shSNHG6‑trans‑fected A375 cells were restored by RAP2B overexpression (Fig. 5D and E). Collectively, the data demonstrated that

SNHG6 may accelerate melanoma progression by increasing RAP2B expression (17).

Discussion

Numerous studies have reported that lncRNAs participate in the regulation of tumor progression (18‑20). In the present study, it was demonstrated that SNHG6 promoted melanoma cell viability, migration and invasion by upregulating RAP2B expression via sponging miR‑101‑3p.

Previous studies have confirmed that lncRNAs can regulate various biological processes, such as proliferation, migration, invasion and apoptosis of melanoma cells (21,22). For instance, lncRNA lung adenocarcinoma associated transcript 1 expression is increased in melanoma via modu‑lation of the miR‑28‑5p/RAP1B axis (23). Moreover, the lncRNA nuclear paraspeckle assembly transcript 1 acceler‑ates melanoma cell proliferation and metastasis by targeting miR‑224 (24), while silencing of metastasis associated lung adenocarcinoma transcript 1 suppresses melanoma develop‑ment via regulating miR‑608/homeobox C4 (25). Recently, SNHG6 was reported to be involved in the tumorigenesis and development of some types of human cancer. For instance, SNHG6 promotes cell proliferation of non‑small‑cell lung carcinoma via regulating miR‑490‑3p/remodeling and

Figure 3. SNHG6 is a sponge for miR‑101‑3p. (A) Binding sequences between SNHG6 and miR‑101 predicted using starBase. (B) RT‑qPCR of the expres‑sion levels of miR‑101‑3p in A375 cells transfected with NC mimics or miR‑101‑3p mimics. (C) Luciferase reporter assay was used to verify the binding ability between SNHG6 and miR‑101‑3p in 293T cells. RT‑qPCR of the expression levels of miR‑101 in (D) melanoma tissues and (E) cell lines. **P<0.01 vs. healthy or HEMa‑LP. (F) RT‑qPCR of the expression levels of miR‑101 in A375 cells transfected with shSNHG6 or shNC. RT‑qPCR of the expres‑sion levels of (G) SNHG6 and (H) miR‑101‑3p after transfection with pcDNA3.1/SNHG6 or pcDNA3.1 in A375 cells. (I) Correlation between SNHG6 and miR‑101‑3p expression in melanoma tissues assessed via Pearson's correlation analysis. *P<0.05; **P<0.01. RT‑qPCR, reverse transcription‑quantitative PCR; miR, microRNA; NC, negative control; sh, short hairpin RNA; wt, wild‑type; mut, mutant; SNHG6, small nucleolar RNA host gene 6; chr, chromosome.

ZHOU et al: lncRNA SNHG6 PROMOTES TUMORIGENESIS VIA THE miR‑101‑3p/RAP2B AXIS IN MELANOMA6

spacing factor 1 (26). Furthermore, SNHG6 promotes hepa‑tocellular carcinoma progression via the miR‑139‑5p/serpin family H member 1 axis (27). However, it is yet to be elucidated whether SNHG6 is involved in the progression of melanoma. In the present study, SNHG6 expression was significantly upregulated in melanoma tissues and cell lines. In addition, the upregulation of SNHG6 was closely associated with patient prognosis. Using loss‑of‑function experiments, the current study demonstrated that knock‑down of SNHG6 inhibited melanoma cell proliferation and migration.

Previous studies have revealed that lncRNAs can act as competing endogenous (ce)RNA for miRNAs in order to modulate human cancer progression (28,29). For example, the lncRNA urothelial cancer associated 1 acts as a ceRNA of miR‑143 to promote prostate cancer progression (30). The lncRNA IGFL2‑AS1 sponges miR‑802 to regulate cAMP regulated phosphoprotein 19 expression in gastric cancer (31). Therefore, the potential targets of SNHG6 were examined in the current study, and miR‑101‑3p was found to bind directly to SNHG6. Several studies have reported that SNHG6 sponges miR‑101‑3p‑3p to modulate cancer progression. For example, Li et al (32) revealed that lncRNA SNHG6 contrib‑uted to the proliferation of non‑small cell lung cancer cells by sponging miR‑101‑3p. Meng et al (33) also reported that

SNHG6 accelerated glioma development via downregulating miR‑101‑3p, while Chang et al (34) indicated that SNHG6 modulated zinc finger E‑box binding homeobox 1 expres‑sion by binding to miR‑101‑3p in hepatocellular carcinoma. However, to the best of our knowledge, no studies have investi‑gated the role of the SNHG6/miR‑101‑3p axis in melanoma. In the present study, SNHG6 was identified to inhibit miR‑101‑3p expression via direct interaction, and a negative correlation was observed between SNHG6 and miR‑101‑3p expression levels in melanoma tissues.

The dysregulation of RAP2B has been reported to be involved in several types of human cancer. For example, Peng et al (35) observed that RAP2B overexpression promotes cell viability and invasion of lung cancer. It has also been shown that miR‑194 attenuates bladder cancer progression by repressing RAP2B (36,37). The lncRNA X inactive specific transcript sponges miR‑320b to upregulate RAP2B expres‑sion in osteosarcoma (37). In the present study, RAP2B was identified as a direct target of miR‑101‑3p. miR‑101‑3p overexpression decreased the expression levels of RAP2B. Furthermore, RAP2B expression exhibited a negative correla‑tion with miR‑101‑3p expression and a positive correlation with SNHG6 expression. It was also demonstrated that silencing of miR‑101‑3p partially abolished the inhibitory effect of SNHG6‑knockdown on RAP2B expression, indicating that

Figure 4. SNHG6 upregulates RAP2B expression by sponging miR‑101‑3p. (A) Binding sequences between RAP2B and miR‑101‑3p predicted using starBase. (B) Luciferase reporter assay was used to verify the interaction between RAP2B and miR‑101 in 293T cells. (C) RT‑qPCR of the expression levels of RAP2B transfected with miR‑101‑3p mimics in A375 cells. (D) RT‑qPCR assay was used to determine RAP2B expression in melanoma and healthy tissues. Correlation between RAP2B expression and (E) miR‑101‑3p or (F) SNHG6 in melanoma tissues was assessed using Pearson's correlation analysis. (G) RT‑qPCR of the expression levels of miR‑101 in A375 cells transfected with NC inhibitor or miR‑101‑3p inhibitor. (H) RT‑qPCR was performed to measure RAP2B expression in A375 cells transfected with shNC, shSNHG6 or shSNHG6 + miR‑101‑3p inhibitor. *P<0.05; **P<0.01. RT‑qPCR, reverse transcription‑quantitative PCR; miR, microRNA; NC, negative control; sh, short hairpin RNA; wt, wild‑type; mut, mutant; SNHG6, small nucleolar RNA host gene 6; chr, chromosome.

ONCOLOGY LETTERS 20: 323, 2020 7

SNHG6 regulated RAP2B expression by sponging miR‑101. Finally, functional analysis revealed that RAP2B overexpres‑sion abrogated the inhibitory effect of SNHG6‑knockdown on

melanoma cell viability, migration and invasion. Collectively, the data indicated that SNHG6 may increase RAP2B expres‑sion by suppressing miR‑101‑3p expression in melanoma cells.

Figure 5. SNHG6 promotes melanoma progression by upregulating RAP2B expression. (A) Reverse transcription‑quantitative PCR assay was performed to assess the expression levels of RAP2B transfected with pcDNA3.1/RAP2B in A375 cells. **P<0.01 vs. pcDNA3.1. (B) Cell Counting Kit‑8 and (C) colony formation assays (magnification, x4) were used to measure cell proliferation in A375 cells after transfection with shNC, shSNHG6 or shSNHG6 and pcDNA3.1/RAP2B. Transwell assays were used to measure (D) migration (magnification, x200) and (E) invasion of A375 cells (magnification, x200) trans‑fected with shNC, shSNHG6 or shSNHG6 + pcDNA3.1/RAP2B. *P<0.05; **P<0.01. shNC, short hairpin RNA negative control; OD, optical density; SNHG6, small nucleolar RNA host gene 6.

ZHOU et al: lncRNA SNHG6 PROMOTES TUMORIGENESIS VIA THE miR‑101‑3p/RAP2B AXIS IN MELANOMA8

In conclusion, the present study demonstrated that SNHG6 may promote melanoma progression via the miR‑101‑3p/RAP2B axis. These findings may provide a novel pathway for melanoma treatment. However, in vivo studies and associated clinical trials are required to verify and elucidate this molecular mechanism.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

HZ and LL designed the present study. HZ, LL, and YW performed the experiments. YW and DW analyzed the data and prepared the figures. HZ and LL drafted the initial manu‑script. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of The First People's Hospital of Changzhou (Changzhou, China) and written informed consent was provided by all patients prior to the study start.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Kozar I, Margue C, Rothengatter S, Haan C and Kreis S: Many ways to resistance: How melanoma cells evade targeted thera‑pies. Biochim Biophys Acta Rev Cancer 1871: 313‑322, 2019.

2. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin 67: 7‑30, 2017.

3. Clarke CA, McKinley M, Hurley S, Haile RW, Glaser SL, Keegan THM and Swetter SM: Continued increase in melanoma incidence across all socioeconomic status groups in California, 1998‑2012. J Invest Dermatol 137: 2282‑2290, 2017.

4. Slipicevic A and Herlyn M: Narrowing the knowledge gaps for melanoma. Ups J Med Sci 117: 237‑243, 2012.

5. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, et al: Melanoma staging: Evidence‑based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67: 472‑492, 2017.

6. Baharara J, Amini E, Nikdel N and Salek‑Abdollahi F: The cytotoxicity of dacarbazine potentiated by sea cucumber saponin in resistant b16f10 melanoma cells through apoptosis induction. Avicenna J Med Biotechnol 8: 112‑119, 2016.

7. Qi P and Du X: The long non‑coding RNAs, a new cancer diag‑nostic and therapeutic gold mine. Mod Pathol 26: 155‑165, 2013.

8. Luan W, Ding Y, Yuan H, Ma S, Ruan H, Wang J, Lu F and Bu X: Long non‑coding RNA LINC00520 promotes the prolif‑eration and metastasis of malignant melanoma by inducing the miR‑125b‑5p/EIF5A2 axis. J Exp Clin Cancer Res 39: 96, 2020.

9. Wan N, Yang W, Cheng H and Wang J: FOXD3‑AS1 contributes to the progression of melanoma Via miR‑127‑3p/FJX1 axis. Cancer Biother Radiopharm 2020 (Epub ahead of print).

10. Yao X, Lan Z, Lai Q, Li A, Liu S and Wang X: lncRNA SNHG6 plays an oncogenic role in colorectal cancer and can be used as a prognostic biomarker for solid tumors. J Cell Physiol 235: 7620‑7634, 2020.

11. Wang H, Wang L, Tang L, Luo J, Ji H, Zhang W, Zhou J, Li Q and Miao L: Long noncoding RNA SNHG6 promotes proliferation and angiogenesis of cholangiocarcinoma cells through sponging miR‑101‑3p and activation of E2F8. J Cancer 11: 3002‑3012, 2020.

12. Li K, Ma YB, Tian YH, Xu XL, Gao Y, He YQ, Pan WT, Zhang JW, He CJ and Wei L: Silencing lncRNA SNHG6 suppresses proliferation and invasion of breast cancer cells through miR‑26a/VASP axis. Pathol Res Pract 215: 152575, 2019.

13. Xiao F, Li Y, Wan Y and Xue M: MircroRNA‑139 sensitizes ovarian cancer cell to cisplatin‑based chemotherapy through regulation of ATP7A/B. Cancer Chemother Pharmacol 81: 935‑947, 2018.

14. Wei H, He WR, Chen KM, Wang XW and Yi CJ: miR‑101 affects proliferation and apoptosis of cervical cancer cells by inhibition of JAK2. Eur Rev Med Pharmacol Sci 23: 5640‑5647, 2019.

15. Li L, Shao MY, Zou SC, Xiao ZF and Chen ZC: miR‑101‑3p inhibits EMT to attenuate proliferation and metastasis in glio‑blastoma by targeting TRIM44. J Neurooncol 141: 19‑30, 2019.

16. Livak KJ and Schmittgen TD: Analysis of relative gene expres‑sion data using real‑time quantitative PCR and the 2(‑Delta Delta C(T)) method. Methods 25: 402‑408, 2001.

17. Marts AR, Kaine JC, Baum RR, Clayton VL, Bennett JR, Cordonnier LJ, McCarrick R, Hasheminasab A, Crandall LA, Ziegler CJ and Tierney DL: Paramagnetic resonance of cobalt(II) trispyrazolylmethanes and counterion association. Inorg Chem 56: 618‑626, 2017.

18. Hu Y, Sun H, Hu J and Zhang X: lncRNA DLX6‑AS1 promotes the progression of neuroblastoma by activating STAT2 via targeting miR‑506‑3p. Cancer Manag Res 12: 7451‑7463, 2020.

19. Qu Y and Liu J: lncRNA MAFG‑AS1 contributes to esopha‑geal squamous‑cell carcinoma progression via regulating miR143/LASP1. Onco Targets Ther 13: 8359‑8370, 2020.

20. Ouyang Q, Cui Y, Yang S, Wei W, Zhang M, Zeng J and Qu F: lncRNA MT1JP suppresses biological activities of breast cancer cells in vitro and in vivo by Regulating the miRNA‑214/RUNX3 axis. Onco Targets Ther 13: 5033‑5046, 2020.

21. An LF, Huang JW, Han X and Wang J: Downregulation of lncRNA H19 sensitizes melanoma cells to cisplatin by regulating the miR‑18b/IGF1 axis. Anticancer Drugs 31: 473‑482, 2020.

22. Liu F, Hu L, Pei Y, Zheng K, Wang W, Li S, Qiu E, Shang G, Zhang J and Zhang X: Long non‑coding RNA AFAP1‑AS1 accelerates the progression of melanoma by targeting miR‑653‑5p/RAI14 axis. BMC Cancer 20: 258, 2020.

23. Xu JH, Zhao WY, Fang QQ, Wang XF, Zhang DD, Hu YY, Zheng B and Tan WQ: Long noncoding RNA LUADT1 is upreg‑ulated in melanoma and may sponge miR‑28‑5p to upregulate RAP1B. Cancer Biother Radiopharm 35: 307‑312, 2020.

24. Zou JX and Ge TW: Long non‑coding RNA NEAT1 promotes tumor development and metastasis through targeting miR‑224‑5p in malignant melanoma. Eur Rev Med Pharmacol Sci 24: 1302‑1308, 2020.

25. Wu S, Chen H, Zuo L, Jiang H and Yan H: Suppression of Long non‑coding RNA MALAT1 inhibits the development of uveal melanoma via microRNA‑608‑mediated inhibition of HOXC4. Am J Physiol Cell Physiol 318: C903‑C912, 2020.

26. Dong Z, Liu H and Zhao G: Long noncoding RNA SNHG6 promotes proliferation and inhibits apoptosis in non‑small cell lung cancer cells by regulating miR‑490‑3p/RSF1 axis. Cancer Biother Radiopharm 35: 351‑361, 2020.

27. Wu G, Ju X, Wang Y, Li Z and Gan X: Up‑regulation of SNHG6 activates SERPINH1 expression by competitive binding to miR‑139‑5p to promote hepatocellular carcinoma progression. Cell Cycle 18: 1849‑1867, 2019.

ONCOLOGY LETTERS 20: 323, 2020 9

28. Ji D, Wang Y, Li H, Sun B and Luo X: Long non‑coding RNA LINC00461/miR‑149‑5p/LRIG2 axis regulates hepatocellular carcinoma progression. Biochem Biophys Res Commun 512: 176‑181, 2019.

29. Zhou FC, Zhang YH, Liu HT, Song J and Shao J: lncRNA LINC00588 suppresses the progression of osteosarcoma by acting as a ceRNA for miRNA‑1972. Front Pharmacol 11: 255, 2020.

30. Yu Y, Gao F, He Q, Li G and Ding G: lncRNA UCA1 functions as a ceRNA to promote prostate cancer progression via sponging miR143. Mol Ther Nucleic Acids 19: 751‑758, 2020.

31. Ma Y, Liu Y, Pu YS, Cui ML, Mao ZJ, Li ZZ, He L, Wu M and Wang JH: lncRNA IGFL2‑AS1 functions as a ceRNA in regulating ARPP19 through competitive binding to miR‑802 in gastric cancer. Mol Carcinog 59: 311‑322, 2020.

32. Li K, Jiang Y, Xiang X, Gong Q, Zhou C, Zhang L, Ma Q and Zhuang L: Long non‑coding RNA SNHG6 promotes the growth and invasion of non‑small cell lung cancer by downregulating miR‑101‑3p. Thorac Cancer 11: 1180‑1190, 2020.

33. Meng Q, Yang BY, Liu B, Yang JX and Sun Y: Long non‑coding RNA SNHG6 promotes glioma tumorigenesis by sponging miR‑101‑3p. Int J Biol Markers 33: 148‑155, 2018.

34. Chang L, Yuan Y, Li C, Guo T, Qi H, Xiao Y, Dong X, Liu Z and Liu Q: Upregulation of SNHG6 regulates ZEB1 expression by competitively binding miR‑101‑3p and interacting with UPF1 in hepatocellular carcinoma. Cancer Lett 383: 183‑194, 2016.

35. Peng YG, Zhang ZQ, Chen YB and Huang JA: Rap2b promotes proliferation, migration, and invasion of lung cancer cells. J Recept Signal Transduct Res 36: 459‑464, 2016.

36. Zhang M, Zhuang Q and Cui L: miR‑194 inhibits cell prolif‑eration and invasion via repression of RAP2B in bladder cancer. Biomed Pharmacother 80: 268‑275, 2016.

37. Lv GY, Miao J and Zhang XL: Long noncoding RNA XIST promotes osteosarcoma progression by targeting Ras‑Related protein RAP2B via miR‑320b. Oncol Res 26: 837‑846, 2018.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.